Loading...
•
Dec 31, 2022
Curis Q4 2022 Earnings Report
Curis reported a net loss for the fourth quarter ended December 31, 2022, and completed enrollment of the 9 additional patients requested by the FDA ahead of schedule in its TakeAim Leukemia study.
Key Takeaways
Curis reported its Q4 2022 financial results, with a net loss of $11.3 million, or $0.12 per share. The company also announced the completion of enrollment for the additional patients requested by the FDA in the TakeAim Leukemia study.
Completed enrollment of 9 additional patients in TakeAim Leukemia study ahead of schedule.
Presented positive updated clinical data from the Phase 1a dose escalation study of emavusertib at the ASH Meeting.
Expects to include data from the 9 additional patients in discussions with FDA in Q3.
Cash, cash equivalents and investments totaled $85.6 million as of December 31, 2022, expected to maintain planned operations into 2025.
Revenue by Segment
Forward Guidance
Curis expects to discuss data from additional patients with the FDA in Q3 to determine RP2D and resolve the partial clinical hold. Existing cash, cash equivalents and investments are expected to enable planned operations into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...